Endocrine Abstracts

Many children have been treated for the diagnosis of GH deficiency during childhood. Having reached final height, it was customary to stop the GH therapy. However, even though final height has been achieved, the adolescent ‘child’ is still in the transition phase as far as peak muscle and bone development are concerned. As this transition period is particularly challenging in adolescents that were treated with GH during childhood it is most important to redefine them correctly and find those who need lifelong substitution. Over the last years many studies have focused on this issues. In this presentation the our protocol to follow-up on these subjects/patients will be presented. In this review the specific focus is on the patients treated for childhood-onset GHD.